EPA-0299 - Agomalatine is effective in reducing insomnia in abstinent alcohol-dependent patients - 01/08/14
Résumé |
Introduction |
Among abstinent alcohol-dependent patients, sleep disorders are a wide-spread and persistent problem and have been associated with the risk of alcohol relapse. The melatonin-agonist agomelatine has been shown to improve overall sleep quality without daytime sedation.
Aims |
To examine the effect of agomelatine on sleep quality in abstinent alcohol-dependet patients suffering from chronic sleep disorders.
Methods |
9 alcohol-dependet patients suffering from chronic sleep disorders received nightly doses between 25 and 50mg of agomelatine. Sleep quality was assesed using the Pittsburgh Sleep Quality Index prior and following 6 weeks of treatment with agomelatine. Prior and during treatment with agomelatine all patients were monitored for serum levels of liver enzymes.
Results |
After 6 weeks of agomelatine treatment, the Pittsburgh Sleep Quality Index global score for all patients had decreased significantly.
Conclusions |
The present data suggest that agomelatine may improve the sleep quality of alcohol-dependent patients suffering from chronic sleep disorders.
Le texte complet de cet article est disponible en PDF.
Vol 29 - N° S1
P. 1 - 2014 Retour au numéro
Article précédent
- EPA-0298 – Pregabalin abuse among opiate addicted patients
- M. Grosshans, T. Lemenager, C. Vollmert, N. Kaemmerer, J. Mutschler, X. Wagner, F. Kiefer, D. Hermann
- EPA-0301 – Improving somatic health of outpatients with severe mental illness
- F. Van Hasselt, M. Oud, P. Krabbe, M. Postma, A. Loonen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?